Print
Share
RSS
Donate
The AZCERT Scientific Review Committee has found that two newly marketed drugs - Vepdegestrand (anti-cancer drug) and Zidesamtinib (anti-cancer drug) - are associated with QT prolongation but lack convincing evidence of causing torsades de pointes (TdP). Therefore, these drugs have been added to the Possible Risk of TdP category (PR) and to the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (DTA List). The committee also found a new drug combination - beclomethasone dipropionate/formoterol fumarate/glycopyrrolate (asthma medication) - that contains an ingredient already found on our DTA list (formoterol fumarate) and will thus be added to the List of Drugs to Avoid in patients with Congenital Long QT Syndrome.
As demonstrated by these revisions, the QTdrugs list is dynamic and changes regularly. To perform a quick search of the QTdrugs and DTA Lists, we recommend using the CredibleMeds website and/or the smartphone app (Apple or Android).
FREE BASIC Version
- Search by generic/brand names
- Notification when List has been revised
- List of major brand names for each drug
- QTdrugs List in 5 languages
